Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre.
about
Preoperative chemotherapy for women with operable breast cancerRelationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancerAn EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.Breast cancer (non-metastatic)Does neoadjuvant chemotherapy increase breast conservation in operable breast cancer: an Egyptian experienceA Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast CancerLetrozole in the neoadjuvant setting: the P024 trial.Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapyEfficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapyEvaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancerPrognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer.Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancerDiagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients.Attitudes towards breast conservation in patients aged over 70 with breast cancer.Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future.Intrinsic resistance to chemotherapy in breast cancer.Surgery and radiotherapy for early breast cancer.Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women.Breast cancer (non-metastatic).Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis.
P2860
Q24245281-056FE333-605B-4591-8B83-F684C9290479Q28364208-C2840A11-7063-4CAA-AAE0-65C6CEBD8C93Q33340401-1C3F0D18-625B-4B30-AC9E-4B3105CDA90EQ33348234-7694444A-51F5-4242-BAE2-DB9FE1F11D1AQ33446778-BF899A5A-F85D-404A-889D-D28FE3BC3162Q35572879-1F9F6DEF-72C9-4D65-B1F3-6FF261B29CF3Q35862343-3B63A2CC-85D5-444D-A413-BA7CA719618CQ36026549-46EBD95A-314D-49C2-8E84-520ED7362CB3Q36092031-A3BC2FD4-961E-4508-861A-E3D437DE51D9Q36134870-22736BF5-9463-46B3-8C3A-B7D2BD327AF3Q36136174-8E507E5C-4FC5-43FB-B6C7-4624DDA49A5BQ36390229-ACB77B3F-CFF3-4CE0-BED6-2F57D4953276Q36431261-6258D7A2-C45F-4CDC-A1EF-C776A7D45DB9Q36431766-CC8BCC3D-3762-4C66-8665-8D9C8E3C9C91Q36615792-860CE389-D6D3-4312-A449-6CD74C210512Q36623843-F514B1D5-9B8D-4BCC-AD10-2951BB8D7BFFQ36641854-AF686B37-0AE4-4C1B-9204-3E1A07B42E33Q36695226-3951D24B-AACF-489A-89BD-21DE9A63D3BEQ36779852-7CC15DC1-2FA6-41DB-BD52-DEAE6E53A2A7Q36809052-7FA781E8-BA8F-4D0C-9A54-335CA715C13EQ37145188-B833A7A5-C5E1-45E1-83C6-A15B5E76B170Q37813694-FB40E129-F09A-4DED-BD40-A4D404700B1FQ42789996-AD51AEBD-8136-405A-9F9D-D9641EC9BDECQ43910372-86F15D83-81E6-40E7-8841-12CB161701EFQ55176357-CA1E52D1-1785-4E5A-9640-EFB8B8F421C1Q55282718-4C6A779D-C10F-484B-9349-D0890803373D
P2860
Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Effects of primary chemotherap ...... ized trial in a single centre.
@en
Effects of primary chemotherap ...... ized trial in a single centre.
@nl
type
label
Effects of primary chemotherap ...... ized trial in a single centre.
@en
Effects of primary chemotherap ...... ized trial in a single centre.
@nl
prefLabel
Effects of primary chemotherap ...... ized trial in a single centre.
@en
Effects of primary chemotherap ...... ized trial in a single centre.
@nl
P2093
P1433
P1476
Effects of primary chemotherap ...... ized trial in a single centre.
@en
P2093
P304
P356
10.1093/OXFORDJOURNALS.ANNONC.A057953
P577
1991-05-01T00:00:00Z